Agenus Poised for Breakthrough with Upcoming Clinical Data
AI Prediction of Agenus Inc. (AGEN)
Agenus Inc. is poised for a significant potential breakthrough with its lead assets botensilimab and balstilimab in the treatment of metastatic colorectal cancer, with upcoming clinical data presentations that could catalyze its stock price.
Agenus Inc., a clinical-stage biotechnology company, focuses on immuno-oncology treatments with its leading candidates botensilimab and balstilimab. These drugs are currently in late-stage clinical trials for metastatic colorectal cancer (mCRC), a market with significant unmet needs. The company is expected to present crucial data at the upcoming AACR 2026 event on April 21, which could substantially impact its valuation and market position. A positive outcome could validate the efficacy of its treatment regimen, potentially leading to accelerated approval and commercialization. This event serves as a critical inflection point for Agenus, offering significant upside potential for investors if the results are favorable.
AGEN Report Information
Prediction Date2026-03-25
Close @ Prediction$3.56
Mkt Cap364m
IPO DateN/a
AI-derived Information
Recent News for AGEN
- Aug 31, 7:30 am — Agenus to Participate in Upcoming September Investor Conferences ((Business Wire))
- Aug 28, 10:07 am — Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism ((Business Wire))
- Aug 26, 10:05 am — Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer ((Business Wire))
- Aug 17, 6:01 am — AGEN SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 11, 4:30 pm — AGEN files 8-K with regulatory language (ScanScor Filing Bot)
- Aug 7, 4:42 pm — Agenus: Q2 Earnings Snapshot (Associated Press)
- Aug 7, 4:30 pm — AGEN SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 7, 4:02 pm — AGEN SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 6, 7:30 am — Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer (Business Wire)
- Jul 28, 4:30 pm — Agenus to Provide Second Quarter 2026 Financial Report and Development Update (Business Wire)
- Jul 17, 10:28 am — Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 (Business Wire)
- Jul 13, 2:25 pm — AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment (Stocktwits)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest